About Contact Us Careers

Acute Sinusitis Treatment Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 3117
Published Date: Sep 02, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Acute Sinusitis Landscape

F. Hoffmann-La Roche Ltd
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Pfizer Inc.
Cerecor, Inc.
Bausch Health Companies Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Amgen Inc.
Novartis AG
Bayer AG
Progenity, Inc.

Browse Key Market Insights with Data Illustration:

Acute Sinusitis Market Size & Share, Growth Forecast 2036

In the News

· August 6, 2020: Novartis AG announced the approval of Xolair as an add-on therapy with intranasal corticosteroids for the treatment of rhinosinusitis with nasal polyps.

Author Credits: Radhika Pawar

Report ID: 3117
Published Date: Sep 02, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of acute sinusitis is estimated at USD 2.37 billion.

Acute Sinusitis Market size was over USD 2.24 billion in 2023 and is anticipated to reach USD 5.6 billion by 2036, growing at around 7.3% CAGR during the forecast period i.e., between 2024-2036. Rising prevalence of sinusitis and growing R&D investment for medical research will impel the market growth.

North America is predicted to hold largest revenue share by 2036, on the back of high prevalence of sinusitis in the region.

The major players in the market are Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Cerecor, Inc., Bausch Health Companies Inc., and others.

Inquiry Before Buying Request Free Sample